Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621751 · ClinicalTrials.gov registry record · NA
Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression
A NA study of Traumatic Brain Injury, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT00621751: Completed NA study of Traumatic Brain Injury, sponsored by Wake Forest University Health Sciences.
NCT00621751 is a NA study of Traumatic Brain Injury that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 70 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621751, a NA study of Traumatic Brain Injury, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if carbamazepine reduces irritability and aggression among individuals with traumatic brain injury
Primary Outcome
Neuropsychiatry Inventory-Irritability (NPI-I) \& Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I \& NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, the primary outcome
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Carbamazepine
Study Locations (1)
North Carolina
- Carolinas Rehabilitation - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2008-02 |
| Est. Completion | 2013-10 |
| Phase | NA |
What the finished NCT00621751 record still lists
NCT00621751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00621751 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00621751 about?
NCT00621751 is a clinical study titled "Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression". The purpose of this study is to determine if carbamazepine reduces irritability and aggression among individuals with traumatic brain injury
What is the current status of trial NCT00621751?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2008-02. Estimated completion is 2013-10.
What conditions does trial NCT00621751 study?
This clinical trial studies the following conditions: Traumatic Brain Injury.
What interventions are being tested in trial NCT00621751?
The interventions under investigation include: Placebo (DRUG), Carbamazepine (DRUG).
Who is sponsoring clinical trial NCT00621751?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00621751 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00621751's enrollment target sits among peer trials
70 96th of 171 higher than 73 of 171 other Traumatic Brain Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
tPBM in Older Adults With Traumatic Brain Injury
RECRUITING · NA
-
Carbon Dioxide Administration and Brain Waste Clearance
RECRUITING · NA
-
TMS-fNIRS Personalized Dosing
RECRUITING · NA
-
Community-based Implementation of Online EmReg
RECRUITING · NA
-
Evaluation of the Abbott i-STAT TBI Biomarker Test
RECRUITING · NA
-
Long-term Brain Stimulation of the Motor Ventral Thalamus (VOP/VIM) to Improve Motor Function
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia